"Pyrrolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed)
| Descriptor ID |
D011760
|
| MeSH Number(s) |
D03.383.773.812
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidinones".
This graph shows the total number of publications written about "Pyrrolidinones" by people in this website by year, and whether "Pyrrolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrrolidinones" by people in Profiles.
-
Kondrikov D, Fulton D, Dong Z, Su Y. Heat Shock Protein 70 Prevents Hyperoxia-Induced Disruption of Lung Endothelial Barrier via Caspase-Dependent and AIF-Dependent Pathways. PLoS One. 2015; 10(6):e0129343.
-
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov; 13(11):927-35.
-
Cannady R, Fisher KR, Durant B, Besheer J, Hodge CW. Enhanced AMPA receptor activity increases operant alcohol self-administration and cue-induced reinstatement. Addict Biol. 2013 Jan; 18(1):54-65.
-
Shamroe CL, Bookstaver PB, Rokas KE, Weissman SB. Update on raltegravir and the development of new integrase strand transfer inhibitors. South Med J. 2012 Jul; 105(7):370-8.
-
Rokas KE, Bookstaver PB, Shamroe CL, Sutton SS, Millisor VE, Bryant JE, Weissman SB. Role of raltegravir in HIV-1 management. Ann Pharmacother. 2012 Apr; 46(4):578-89.
-
Albrecht H. Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this year. J Watch AIDS Clin Care. 2010 Jan; 22(1):4.
-
Bartels JW, Billings PL, Ghosh B, Urban MW, Greenlief CM, Wooley KL. Amphiphilic cross-linked networks produced from the vulcanization of nanodomains within thin films of poly(N-vinylpyrrolidinone)-b-poly(isoprene). Langmuir. 2009 Aug 18; 25(16):9535-44.
-
Albrecht H. Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disaster. J Watch AIDS Clin Care. 2009 Apr; 21(4):30-1.
-
Smothers CT, Woodward JJ. Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. J Pharmacol Exp Ther. 2007 Aug; 322(2):739-48.
-
Liu R, Bell PD, Peti-Peterdi J, Kovacs G, Johansson A, Persson AE. Purinergic receptor signaling at the basolateral membrane of macula densa cells. J Am Soc Nephrol. 2002 May; 13(5):1145-51.